Immunotherapy News and Research

Latest Immunotherapy News and Research

Isis Innovation, Ludwig Cancer Research announce launch of new cancer immunotherapy spinout

Isis Innovation, the University of Oxford's technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, iOx Therapeutics. iOx Therapeutics will develop a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford's Weatherall Institute of Molecular Medicine.

9 Jul 2015

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

9 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Natural killer cells of the immune system can fend off malignant lymphoma cells and thus are considered a promising therapeutic approach. However, in the direct vicinity of the tumor they lose their effect.

8 Jul 2015

ImmunID announces publication of clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

ImmunID today announced the publication of a short report in the Journal for ImmunoTherapy of Cancer showing that the analysis of peripheral T cell receptor diversity using the company's ImmunTraCkeR assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma.

8 Jul 2015

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the independent Data Safety Monitoring Board recommends the continuation, per protocol, of its phase 2 clinical trial of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.

8 Jul 2015

ACCC launches new initiative to facilitate adoption of immuno-oncology in community cancer setting

The Association of Community Cancer Centers today launches the Institute for Clinical Immuno-Oncology, the first of its kind initiative aimed to rapidly facilitate the adoption of immuno-oncology in the community cancer setting.

8 Jul 2015

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.

8 Jul 2015

New research reveals why some kids can have severe allergic reaction hours later

Parents of kids with severe allergies know how scary a severe allergic reaction (anaphylaxis) is. New research offers clues as to why some kids can have a second, related reaction hours later - and what to do about it.

8 Jul 2015

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.

7 Jul 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

Damon Runyon creates new award to increase number of physician-scientists

Physician-scientists are crucial to moving scientific discoveries from the lab to patients, but their numbers have been dwindling just when they are needed most, particularly in cancer research, as the number of cancer cases is projected to increase by 45 percent in the next fifteen years and elevate cancer to the leading cause of death in America.

1 Jul 2015

$FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease$

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease.

30 Jun 2015

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia.

29 Jun 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Experimental new treatment approach can send deadly leukemia into remission

An experimental new treatment approach for a rare, deadly leukemia can send the disease into remission even in patients for whom the standard therapy has failed, buying them more time to have the stem cell transplant that could save their lives, a small pilot study has found.

26 Jun 2015

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

For the first time, researchers at Fred Hutchinson Cancer Research Center have found that weight loss, in combination with vitamin D supplementation, has a greater effect on reducing chronic inflammation than weight loss alone. Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.

26 Jun 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Isis Innovation, Ludwig Cancer Research announce launch of new cancer immunotherapy spinout

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

ImmunID announces publication of clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

DSMB recommends continuation of Genticel’s GTL001 phase 2 trial in HPV-infected women

ACCC launches new initiative to facilitate adoption of immuno-oncology in community cancer setting

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

New research reveals why some kids can have severe allergic reaction hours later

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

Damon Runyon creates new award to increase number of physician-scientists

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Experimental new treatment approach can send deadly leukemia into remission

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in